. Author manuscript; available in PMC: 2024 Mar 6.

Published in final edited form as: Pract Radiat Oncol. 2020 Mar 23;10(3):158–173. doi: 10.1016/j.prro.2020.02.009

Table 4.

Recommendations for SBRT in stage I or II node negative SCLC

KQ2 Recommendations	Strength of Recommendation	Quality of Evidence (Refs)

• 1. For patients with stage I or II node negative LS-SCLC who are medically inoperable, either SBRT or conventional fractionation is recommended. •Implementation Remarks: ∘ • Ideally the node negative status should be confirmed by invasive nodal staging. ∘ • Ultracentral tumors may be more appropriately treated with conventional fractionation schema.	Strong	Moderate ²⁰,62, 63, 64
• 2. For patients with stage I or II node negative LS-SCLC receiving SBRT, chemotherapy should be delivered to patients in whom it is medically tolerated.	Strong	Moderate ^18,62,63

Abbreviations: KQ = key question; LS = limited-stage; SBRT = stereotactic body radiation therapy; SCLC = small cell lung cancer.